# Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

> **NCT03252353** · PHASE3 · UNKNOWN · sponsor: **Chiasma, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** octreotide capsules
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT03252353
- **Lead sponsor:** Chiasma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-01
- **Primary completion:** 2019-06-13
- **Final completion:** 2022-05
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03252353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03252353, "Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03252353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*